Cardiff Oncology (CRDF) Net Cash Flow (2011 - 2025)

Cardiff Oncology has reported Net Cash Flow for 15 years, with the latest figure at $7.3 million in Q4 2025.

• Quarterly Net Cash Flow fell 80.91% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$34.0 million (down 214.04% YoY) and the FY2025 annual result came in at -$34.0 million, down 214.04% from the prior year.
• Net Cash Flow rose to $7.3 million in Q4 2025 per CRDF's latest filing, from -$649000.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $38.4 million in Q4 2024 and troughed at -$116.3 million in Q1 2021.
• A 5-year average of -$5.7 million and a median of -$1.3 million in 2021 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2021 and 2024: Net Cash Flow slumped 12570.92% in 2021, then surged 498.44% in 2024.
• Over 5 years, Net Cash Flow stood at -$1.2 million in 2021, then tumbled by 93.94% to -$2.4 million in 2022, then soared by 370.97% to $6.4 million in 2023, then soared by 498.44% to $38.4 million in 2024, then tumbled by 80.91% to $7.3 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered $7.3 million, -$649000.0, and -$13.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.